Interceptor for Dogs 2-10 lbs, 6 Month (Brown) flavor tabs protects from potentially fatal heartworm disease in dogs.
Interceptor for dogs brown is available in palatable, chewable tabs for easy administration that protect against multiple parasitic threats including hookworm, roundworm, and whipworm.
These dog tables for heartworm treatment for dogs are manufactured by Novartis Animal Health US, Inc.
Now order Interceptor for dogs brown and other heartworm meds from our pet pharmacy online store based in Texas and get the pet prescription medication delivered at your doorstep.
- Can be used year-round, not just during mosquito season
- Prevents potentially fatal heartworm disease in dogs
- Once-a-month flavor tabs
INFORMATION FOR DOSING DOGS
The palatable once-a-month dog tablets prevent heartworm disease in dogs, controls adult hookworm, and remove and controls adult roundworm and whipworm infections in dogs and puppies.
Federal (USA) law restricts this pet med to use by or on the order of a licensed veterinarian. Keep this and all drugs out of the reach of children.
INTERCEPTOR for dogs is available in four tablet sizes in color-coded packages for oral administration to dogs and puppies. Each dog tablets is formulated to provide a minimum of 0.23 mg/lb (0.5 mg/kg) body weight of milbemycin oxime.
Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3(C31H43NO7, MW 541.68).
|Package color||Milbemycin oxime tablet|
*for dogs only
INTERCEPTOR Flavor Tabs are indicated for use in the prevention of heartworm disease in dogs caused by Dirofilaria immitis, the control of adult Ancylostoma caninum (hookworm), and the removal and control of adult Toxocara canis and Toxascaris leonina (roundworms) and Trichuris vulpis (whipworm) infections in dogs and in puppies four weeks of age or greater and two pounds body weight or greater.
INTERCEPTOR dog medicine is given orally, once a month, at the recommended minimum dosage rate of 0.23 mg milbemycin oxime per pound of body weight (0.5 mg/kg).
Recommended Dosage Schedule for Dogs
|Body Weight||INTERCEPTOR Flavor Tabs|
|2-10 lbs.||One tablet (2.3 mg)|
|11-25 lbs.||One tablet (5.75 mg)|
|26-50 lbs.||One tablet (11.5 mg)|
|51-100 lbs.||One tablet (23.0 mg)|
Dogs over 100 lbs. are provided the appropriate combination of tablets.
INTERCEPTOR for dogs is palatable and most dogs will consume the tablet willingly when offered by the owner. As an alternative, the dual-purpose dog tablets may be offered in food or administered as other tablet medications. Watch the dog closely following dosing to be sure the entire dose has been consumed. If it is not entirely consumed, redose once with the full recommended dose as soon as possible.
This dog heartworm medication must be administered monthly, preferably on the same date each month. The first dose should be administered within one month of the dog’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. If a dose is missed and a 30-day interval between dosing is exceeded, administer this dog meds immediately and resume the monthly dosing schedule.
If INTERCEPTOR dog medicine replaces diethylcarbamazine (DEC) for heartworm prevention, the first dose must be given within 30 days after the last dose of DEC.
Palatability trials conducted in 244 dogs from 10 different U.S. veterinary practices demonstrated that INTERCEPTOR heartworm meds were willingly accepted from the owner by over 95% of dogs. The trial was comprised of dogs representing 60 different breeds and both sexes, with weights ranging from 2.1 lbs. to 143.3 lbs., and ages ranging from 8 weeks to 15 years.
Do not use this heartworm medicine for dogs in puppies less than four weeks of age or less than two pounds of body weight. Prior to initiation of the dog heartworm preventative treatment program, dogs should be tested for existing heartworm infections. Infected dogs should be treated to remove adult heartworms and microfilariae prior to initiating treatment with INTERCEPTOR dog medicine. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some treated dogs carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.
The following adverse reactions have been reported following the use of INTERCEPTOR heartworm medicine for dogs: Depression/lethargy, vomiting, ataxia, anorexia, diarrhea, convulsions, weakness and hypersalivation.
INTERCEPTOR for Dogs eliminate the tissue stage of heartworm larvae and the adult stage of hookworm (Ancylostoma caninum), roundworms (Toxocara canis, Toxascaris leonina) and whipworm (Trichuris vulpis) infestations when administered orally according to the recommended dosage schedule. The anthelmintic activity of milbemycin oxime is believed to be a result of interference with invertebrate neurotransmission.
Milbemycin oxime has been tested safely in over 75 different breeds of dogs, including collies, pregnant females, breeding males and females, and puppies over two weeks of age. In well-controlled clinical field studies, 786 dogs completed treatment with milbemycin oxime. Milbemycin oxime was used safely in animals receiving frequently used veterinary products for dogs such as vaccines, anthelmintics, antibiotics, steroids, flea collars, shampoos and dips.
Two studies in heartworm-infected dogs were conducted which demonstrated mild, transient hypersensitivity reactions in treated dogs with high microfilaremia counts (see Precautions for reactions observed). Safety studies in pregnant dogs demonstrated that high doses (1.5 mg/kg = 3X) of milbemycin oxime given in an exaggerated dosing regimen (daily from mating through weaning), resulted in measurable concentrations of the drug in milk. Puppies nursing these females which received exaggerated dosing regimens demonstrated milbemycin-related effects. These effects were directly attributable to the exaggerated experimental dosing regimen. The product is normally intended for once-a-month administration only. Subsequent studies included using 3X daily from mating to one week before weaning and demonstrated no effects on the pregnant females or their litters. A second study where pregnant females were dosed once at 3X the monthly use rate either before, on the day of or shortly after whelping resulted in no effects on the puppies.
Some nursing puppies, at 2, 4, and 6 weeks of age, given greatly exaggerated oral milbemycin oxime doses (9.6 mg/kg = 19X) exhibited signs typified by tremors, vocalization and ataxia. These effects were all transient and puppies returned to normal within 24 to 48 hours. No effects were observed in puppies given the recommended dose of milbemycin oxime (0.5 mg/kg). This dog medicine product has not been tested in dogs less than 1 kg weight.
A rising-dose safety study conducted in rough-coated collies manifested a clinical reaction consisting of ataxia, pyrexia and periodic recumbency, in one of fourteen dogs treated with milbemycin oxime at 12.5 mg/kg (25X monthly use rate). Prior to receiving the 12.5 mg/kg dose (25X monthly use rate) on day 56 of the study, all animals had undergone an exaggerated dosing regimen of this pet prescription medication consisting of 2.5 mg/kg milbemycin oxime (5X monthly use rate) on day 0, followed by 5.0 mg/kg (10X monthly use rate) on day 14 and 10.0 mg/kg (20X monthly use rate) on day 32. No adverse reactions were observed in any of the collies treated with this regimen up through the 10.0 mg/kg (20X monthly use rate) dose.
INTERCEPTOR heartworm medication for dogs is available in four tablet sizes, formulated according to the weight of the dog. Each tablet size is available in color-coded packages of 6 or 12 tablets each, which are packaged 10 per display carton.
INTERCEPTOR for dogs Brown to treat heartworm disease in dogs should be stored at room temperature, between 59° and 77°F (15-25°C).
Manufactured for: Novartis Animal Health US, Inc.,
Greensboro, NC 27408, USA
NADA #140-915, Approved by FDA
INTERCEPTOR and Flavor Tabs are registered trademarks of Novartis AG.